๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Colorectal Cancer Metastatic
Clinical trial register · China

Colorectal Cancer Metastatic Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 6 Beijing 6 Shanghai 6 Hangzhou 4 Xi'an 1
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou6 Beijing6 Shanghai6 Hangzhou4 Xi'an1
All 10 locations
Target enrolment
to

Colorectal Cancer Metastatic trials in China

28 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC
NCT07729605Colorectal Cancer Metastatic, Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Sun Yat-sen University
Phase 3
270
Guangzhou
2026-07-30
Not yet open
SHR-A1904 in Advanced Colorectal Cancer: an Exploratory Study
NCT07700719Colorectal Cancer Metastatic
Peking University Cancer Hospital & Institute
Phase 2
17
Beijing
2026-07-28
Not yet open
A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer
NCT07621159Colorectal Cancer Metastatic
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1/2
120
Beijing
2026-07-15
Recruiting
A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
NCT06889610Triple Negative Breast Cancer Metastatic, Melanoma Metastatic, Colorectal Cancer Metastatic
Fudan University
Phase 2
95
Shanghai
2026-03-30
Recruiting
Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer
NCT07462650Colorectal Cancer Metastatic, Adenocarcinoma of Colon
Beijing Biotech
Phase 1/2
48
Shenzhen
2026-02-01
Not yet open
Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
NCT07014254Pancreatic Ductal Adenocarcinoma (PDAC), Adenocarcinoma of the Stomach, Colorectal Cancer Metastatic, Neuroendocrine Tumor (NET)
Xijing Hospital
Not applicable
20
Xi'an
2025-06-20
Recruiting
A Dose-Expansion Trial of Intravenous HNF4ฮฑ srRNA for Unresectable or Metastatic Colorectal Cancer
NCT07050394Colorectal Cancer Metastatic, Colorectal Cancer Recurrent, Colorectal Cancer Stage IV
Shanghai Changzheng Hospital
Phase EARLY_PHASE1
20
Shanghai
2025-06-10
Recruiting
ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC
NCT07012954Colorectal Cancer Metastatic
Sun Yat-sen University
Phase 1/2
64
Guangzhou
2025-06-01
By invitation
The Efficacy and Safety of IBI351, Cetuximab ฮฒ Combined With FOLFIRI as First-line /IBI351, Cetuximab ฮฒ as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer
NCT06959589Colorectal Cancer Metastatic, KRAS G12C Mutation
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
50
Hangzhou
2025-05-22
Recruiting
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
NCT06589830Colorectal Cancer Metastatic, Advanced Colorectal Cancer
Suzhou Teligene Ltd.
Phase 2
80
Beijing
2025-05-13
Not yet open
Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis
NCT06973343Colorectal Cancer Metastatic
Anhui Provincial Cancer Hospital
Phase 2
20
Hefei
2025-05
Recruiting
Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer
NCT06992648Colorectal Cancer Metastatic, Colorectal Cancer Recurrent
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
302
Hangzhou
2025-04-01
Recruiting
Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer
NCT06763029Colorectal Cancer Metastatic
Fudan University
Phase 2
36
Shanghai
2025-02-26
Recruiting
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
NCT06764680Colorectal Cancer Metastatic, Chemotherapy, Targeted Therapy, Immunotherapy
Sun Yat-sen University
Phase 2
57
Guangzhou
2024-12-31
Not yet open
SHR-1701 Combined with SHR2554 and BP102 for MCRC
NCT06679673Colorectal Cancer Metastatic
Fudan University
Phase 2
20
Shanghai
2024-12
Recruiting
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
NCT06540326Colorectal Cancer Metastatic
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
100
Hangzhou
2024-11-12
Recruiting
Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.
NCT07044921Colorectal Cancer Metastatic
Chinese PLA General Hospital
Phase 2
30
Beijing
2024-09-01
Recruiting
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
NCT06685276Colorectal Cancer Metastatic
Dai, Guanghai
Phase 2
46
Beijing
2024-08-16
Recruiting
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
NCT06547203Colorectal Cancer Metastatic
Sun Yat-sen University
Phase 2
34
Guangzhou
2024-07-18
Recruiting
Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC
NCT06456515Colorectal Cancer Metastatic
The First People's Hospital of Changzhou
Not applicable
30
Changzhou
2024-05-01
Recruiting
Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
NCT06282445Colorectal Cancer Metastatic
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 2
36
Jinhua
2024-03-01
Recruiting
Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA
NCT06440902Colorectal Cancer Metastatic
Fudan University
Phase 2
1,100
Shanghai
2023-12-28
Recruiting
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
NCT06008119Colorectal Cancer Metastatic
Shanghai Kechow Pharma, Inc.
Phase 3
165
Beijing
2023-10-25
Active, closed
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
NCT06792435Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic
Astellas Pharma Global Development, Inc.
Phase 1/2
240
Jinan
2023-07-27
Recruiting
Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Surgery by Multi-omics Methods
NCT05501353Colorectal Cancer Metastatic
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
125
Hangzhou
2022-07-22
Recruiting
Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
NCT05057052Liver Metastases, Colorectal Cancer Metastatic
Fudan University
Phase 2
25
Shanghai
2021-09-26
Active, closed
Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients
NCT04940546Colorectal Cancer Metastatic
Sun Yat-sen University
Phase 1/2
36
Guangzhou
2021-06-16
Rows per page Showing 1–28 of 28
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/condition/colorectal-cancer-metastatic

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 28 of those studies listing the condition Colorectal Cancer Metastatic.

How many Colorectal Cancer Metastatic trials are recruiting in China?

19 of the 28 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 6 have not yet opened recruitment, 2 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Colorectal Cancer Metastatic), 28 studies
PhaseStudiesRecruitingShare
Phase 2161257.1%
Phase 1/25217.9%
Phase 33210.7%
Not applicable217.1%
Observational113.6%
Phase EARLY_PHASE1113.6%

Most active sponsors

Lead sponsors with the most studies (Colorectal Cancer Metastatic)
Lead sponsorStudiesRecruiting
Sun Yat-sen University64
Fudan University54
Second Affiliated Hospital, Zhejiang University, School of Medicine43
Anhui Provincial Cancer Hospital10
Astellas Pharma Global Development, Inc.10
Beijing Biotech11
Chinese PLA General Hospital11
Dai, Guanghai11
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.10
Peking University Cancer Hospital & Institute10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.